Related Experiment Videos
[Small cell carcinoma of the prostate]
J M Alapont Alacreu1, M J Montaner Ramírez, J L Pontones Moreno
1Servicio de Urología, Hospital Universitario La Fe, Valencia.
Actas Urologicas Espanolas
|November 27, 2002
Summary
Pure small cell carcinoma of the prostate is a rare and aggressive cancer. Despite temporary remission with chemotherapy, it has a poor prognosis and short survival, necessitating further research.
Area of Science:
- Oncology
- Urology
Background:
- Pure small cell carcinoma of the prostate is an exceptionally rare malignancy, accounting for less than 1% of all prostate neoplasms.
- Literature reports on this specific prostatic cancer are scarce, with fewer than 200 cases documented.
Observation:
- Small cell carcinomas of the prostate represent a heterogeneous tumor group, often exhibiting neuroendocrine differentiation.
- These tumors are characterized by high aggressiveness and frequently present with visceral metastases at the time of diagnosis.
Findings:
- While chemotherapy can induce complete temporary remission, the overall prognosis for prostatic small cell carcinoma remains poor.
- The median overall survival for patients diagnosed with this condition ranges narrowly between 5 to 17.5 months.
Implications:
- The rarity and aggressive nature of prostatic small cell carcinoma highlight the need for improved diagnostic and therapeutic strategies.
- Further research into the management and understanding of neuroendocrine prostatic tumors is crucial for improving patient outcomes.